anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Seven clinically stable patients who have been undergoing CPD for at least six months will be admitted to the General Clinical and Research Center (GCRC) at Harbor-UCLA Medical Center for 46 days. During this time they will be fed, under strict metabolic balance study conditions, a constant energy and protein intake designed to meet their previously ascertained nutritional needs. Their dietary intakes of phosphorus, calcium and magnesium will be maintained constant throughout the 46 days of study at 1100 mg/day, 1000 mg/day and 200 mg/day, respectively. Patients will be treated throughout the study with a constant peritoneal dialysis regimen that consists of either continuous ambulatory peritoneal dialysis with four dialysate exchanges daily or automated peritoneal dialysis in which they will each receive about four dialysate exchanges per night; and possibly day-time dialysate exchanges. The number and volume of dialysate exchanges and the dialysate glucose concentration may vary among patients according to their metabolic and clinical needs, but will be constant for each patient. Patients will adhere to standard metabolic balance protocols as the investigators have conducted during our many previous metabolic balance studies. These protocols will include participating in prescribed daily exercise regimens that are designed to maintain the patients' physical activity at their prestudy, outpatient levels.

All patients will first undergo a 10 day Baseline period for metabolic equilibration during which time they will not receive any phosphate binder. They will then receive three periods of Fosrenol treatment with three different dose levels for 12 days each. During each of three periods, the patients will receive, in random order, one or two Fosrenol tablets that will provide 500, 1000, or 1500 mg with each of the three meals that they will be fed each day. Thus these CPD patients will receive in random order 1500, 3000 and 4500 mg/day of Fosrenol each prescribed for one 12 day period.

Outcome Measurements. All urine, collected in 24 hour urine specimens, and all feces excreted, collected over four day periods, will be obtained continuously. Every 4 days a duplicate 24 hour diet will be prepared for chemical analyses. The above specimens will be analyzed for phosphorus, calcium and nitrogen by spectrographic, atomic absorption spectroscopic and Kjeldahl analyses, respectively. Serum phosphorus, calcium, parathyroid hormone (PTH), fibroblast growth factor-23, 25-hydroxycholecalciferol (25(OH)D3), 1,25-dihydroxycholecalciferol (1,25(OH)2D3), fetuin-A, urea and creatinine will be measured in the fasting state at the beginning of the 40 day balance period and every 5 days. Anthropometry and other standard measurements that are routinely conducted during metabolic balance procedures will also be performed.
OBJECTIVES: The increase in gabapentinoid prescribing is paralleling the increase in serious harms. To describe the low back pain workers compensation population whose management included a gabapentinoid between 2010 and 2017, and determine secular trends in, and factors associated with gabapentinoid use.
METHODS: We analysed claim-level and service-level data from the Victorian workers' compensation programme between 1 January 2010 and 31 December 2017 for workers with an accepted claim for a low back pain injury and who had programme-funded gabapentinoid dispensing. Secular trends were calculated as a proportion of gabapentinoid dispensings per year. Poisson, negative binomial and Cox hazards models were used to examine changes over time in incidence and time to first dispensing.
RESULTS: Of the 17 689 low back pain claimants, one in seven (14.7%) were dispensed at least one gabapentinoid during the first 2 years (n=2608). The proportion of workers who were dispensed a gabapentinoid significantly increased over time (7.9% in 2010 to 18.7% in 2017), despite a reduction in the number of claimants dispensed pain-related medicines. Gabapentinoid dispensing was significantly associated with an opioid analgesic or anti-depressant dispensing claim, but not claimant-level characteristics. The time to first gabapentinoid dispensing significantly decreased over time from 311.9 days (SD 200.7) in 2010 to 148.2 days (SD 183.1) in 2017.
CONCLUSIONS: The proportion of claimants dispensed a gabapentinoid more than doubled in the period 2010-2017; and the time to first dispensing halved during this period.
Clinical studies of Dantrium did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience in the literature has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. As with all patients receiving Dantrium, it is recommended that elderly patients receive the lowest dose compatible with the optimal response. Spontaneous reports suggest a higher proportion of hepatic events with fatal outcome in elderly patients receiving Dantrium. However, the majority of these cases were complicated with confounding factors such as intercurrent illnesses and/or concomitant potentially hepatotoxic medications (for hepatotoxicity details and its management see Black Box and Warnings Sections).
Objective: To explore the association between aldehyde dehydrogenase 2 (ALDH2) gene polymorphisms and abnormal liver function-induced by acetaminophen (APAP) drugs. Methods: An ALDH2 gene knockout mouse model was constructed using CRISPR/Cas9 gene editing technology. The obtained heterozygous mice were mated with opposite sex of heterozygotes. Genomic DNA was extracted from the tail of the offspring mouse. The polymerase chain reaction (PCR) method was used to determine the ALDH2 genotype. APAP was further used to induce acute drug-induced liver injury models in wild-type and ALDH2 knockout mice. Blood and liver tissues of mice were collected for liver function index, HE staining, F4/80 immunohistochemistry, and other detections. The intergroup mean was compared using a one-way ANOVA. The LSD- t test was used for pairwise comparison. Results: ALDH2 knockout mice were bred successfully. The genotyping of the offspring was segregated into the wild-type (ALDH2(+/+)), heterozygous mutant (ALDH2(+/-)), and homozygous mutant (ALDH2(-/-)), respectively. Biochemical and histological results after APAP modeling showed that the level of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBil) was not significantly increased in the blank control group (P < 0.05), while the ALT, AST,ALP, and TBil were all elevated in the APAP experimental group. The levels of ALT (P  = 0.004), AST (P = 0.002), and TBil (P = 0.012) were significantly elevated among the mutant group compared to those in the wild-type group, and the expression levels of these indicators were also significantly elevated among the homozygous mutant group compared to those in the heterozygous mutant group (P = 0.003, 0 and 0.006). In addition, the ALP levels were higher in the heterozygous mutation group than those in the homozygous mutant group (P = 0.085) and wild-type group mice, but the difference was only statistically significant compared to wild-type mice (P = 0.002). HE staining results showed that mice in the APAP experimental group had hepatocyte degeneration, necrosis, and increased inflammatory cell infiltration, which was mostly evident in mutant mice. Simultaneously, the F4/80 immunohistochemical staining results showed that brown granules were visible in the liver tissue of APAP experimental group mice, and its expression levels were significantly enhanced compared to the blank control group. Conclusion: APAP-induced liver function abnormalities were associated with the ALDH2 gene polymorphism. The liver injury symptoms were increased in ALDH2 mutant mice following APAP modeling, and the ALDH2 gene defect may alleviate, to some extent, APAP-induced liver function abnormalities.
A cat dander allergen challenge model was used to collect data for all of the Outcome Measures. The cat allergen levels in the model are similar to those found in homes with cats and are capable of inducing lower- and upper-airway responses that have been used to assess the efficacy of several asthma and allergy therapies.

Cat allergen exposure was performed in a room furnished with upholstered furniture, a blanket, and a cat litter box. The door was kept closed at all times, except when personnel or study patients were entering or leaving the room. The ventilation system was operating at all times except during cat allergen challenges. Two neutered adult cats were kept in the room at all times and were free to move about except during challenges, at which time they are placed in wire cages. Immediately before a challenge, the blanket was shaken vigorously to distribute cat allergen throughout the room.
The present invention discloses a method for synthesizing titanium dioxide based on glutamine modification, and relates to the technical field of biological pharmaceutics, the method comprising the following steps: S1. selecting raw materials; S2. preparing a mixed solution A; S3. preparing a mixed solution B; S4. preparing sol; S5. preparing gel; S6. preparing dry gel powder: the wet gel is dried at 100°C for 12 hours, and then ground into powder, and the powder is calcined at 300°C for 1 hour to remove organic matter; S8. analysing titanium dioxide. By means of the method for synthesizing titanium dioxide based on glutamine modification, copper ions are doped into the crystal lattice of nano-particles to reduce the stability and the energy of the crystal lattice, so that the nano-particles are reacted with glutamine under neutral conditions to obtain nano- titanium dioxide modified with glutamine, thereby realizing the modification of the nano-titanium dioxide with glutamine and the synthesis of glutamine-nano-titanium dioxide which is verified by the ultraviolet, infrared, SEM, EDX, and XRD characterization.
The control group will complete the first three assessments similar to the two treatment groups but will not participate in the nature-based or virtual mindfulness interventions. At the end of their study participation (\~week 3), they will be offered the opportunity to partake in the nature-based and virtual mindfulness interventions.
NEW MATERIAL:The compound of formulaI(R1-R5 are 1-5C alkyl). EXAMPLE:N-(1-Methylethyl)-3,4,5-trimethoxycinnamide. USE:Antispasmodic agent having excellent antispasmodic activity. PROCESS:The compound of formulaIcan be prepared by reacting the compound of formula II (X is halogen) with the compound of formula III in an organic solvent (e.g. benzene) in the presence of a hydrogen halide acceptor such as pyridine, at 0-80 deg.C for 0.5-8hr. The molar ratio of the compound of formula II to the compound of formula III is preferably 1.0-2.0.
Rationale: Antimicrobials are an indispensable part of modern medicine. However, optimal prescription of these agents is becoming increasingly challenging because of the growing complexity of guidelines, and constantly changing epidemiology of infectious pathogens. Moreover, due to local variations in the prevalence of certain pathogens and antimicrobial resistance (AMR), antimicrobial choices need to be tailored to local epidemiology. Improvement of antimicrobial use, in particular prevention of overuse and suboptimal use of antimicrobials, through antimicrobial stewardship (AMS) programs is increasingly regarded as indispensable, both to optimize therapy for the individual patients as well as to reduce emergence and spread of AMR. With the widespread use of electronic health records (EHR) and handheld electronic devices in hospitals, informatics-based AMS interventions hold great promise as tools to improve antimicrobial prescribing. However, they are still underdeveloped, understudied and underutilized.

Objective: The study aims to adapt and evaluate the "AB-assistant", a smartphone based digital stewardship application that is customizable to local guidelines by local antibiotic stewards and therefore has the potential to be used worldwide, including in low- and middle-income countries.

Study design: The existing North American Spectrum app (SpectrumMD; Canada) will be adjusted and translated for the European market. During a usability study physicians will use the app for two weeks followed by individual interviews to determine facilitators and barriers of app use. Based on the results of these interviews the app will be adjusted if necessary. After adaptation and usability testing, thereafter the AB-assistant app will be evaluated in an international, multicentre, randomized clinical trial involving centres in 3 countries in different settings with appropriate antimicrobial use as a primary outcome. In a stepped wedge cluster randomized trial, wards will be randomised after stratification for specialty. At baseline a 2-week measurement period will be done, followed by the introduction of the intervention to 6 wards (in 3 hospitals) with a 4-week interval with 6 inclusion periods. This cycle will be repeated with the inclusion of all new intervention wards. We include the 36 wards in total during the 6 inclusion phases and at the end of the inclusion time we allow use of the app by everyone, also wards not included in the study.
PROBLEM TO BE SOLVED: To obtain the subject medicine which possesses excellent depressant activity for cancer metastasis and can reduce the side effect and sustain the activity by containing a protein like thrombomodulin(TM) as an active ingredient. SOLUTION: This medicine contains a protein like TM (preferably a protein like TM arising from human, more preferably a natural type protein like soluble TM arising from human urine or a protein like gene recombination human soluble TM) as an active ingredient. This medicine is administrated by intraarterial injection, intravenous injection and oral administration. In this case, the protein like TM is administrated daily in a dose of about 0.01-1000μg/kg, preferably about 0.1-500μg/kg, as the amount of protein. When this medicine is used as preparations for external use, the concentration of the protein like TM may be, for example, about 0.001-1000μg/ml, preferably 0.01-500μg/ml. By this process, a clinically efficient effect is expected.
The present invention relates to a Chinese traditional medicine for treating male infertility, which is made by preparing the following components by weight: 4 to 6 portions of prepared rhizome of rehmannia, 3 to 4 portions of Chinese yams, 3 to 4 portions of taros, 2 to 3 portions of dodders, 3 to 4 portions of plantain seeds, 2 to 3 portions of schisandra, 2 to 3 portions of raspberries, 2 to 3 portions of HERBA CISTANCHES, 2 to 3 portions of FRUCTUS LYCII, 2 to 3 portions of psoralea fruits, 1.8 to 2 portions of cynomorium and 2 to 3 portions of epimedium. Each component of the present invention keeps one eye on yin and yang in view of the principal contradiction of deficiency of kidney-essence, wherein the prepared rhizome of rehmannia, the Chinese yams, the taro meat, the dodders and the raspberries tonify the kidney and replenish essence, the HERBA CISTANCHES, the cynomorium and the HERBA EPIMEDII lay particular stress on strengthening yang, and the FRUCTUS LYCII and the taro meat lay particular stress on nourishing Yin, namely YANG hiding in YIN and yin hiding in yang, which results in that YIN matched with sufficient YANG makes living things fully vivid and YANG matched with adequate YIN makes living things freely grow and flourish. Combining various components makes the kidney essence sufficient, and yin and yang are combined. Therefore, a child can be born. A patient basically has no pains when treated by the Chinese traditional medicine of the present invention and takes the treatment by the Chinese traditional medicine in good part. Moreover, the Chinese traditional medicine has reliable curative effect and no side effect and can greatly improve the curative ratio of male infertility.
BACKGROUND: Previous research showed that deviations in longitudinal data are heritable and can be used as a proxy for pigs' general resilience. However, only a few studies investigated the relationship between these resilience traits and other traits related to resilience and welfare. Therefore, this study investigated the relationship between resilience traits derived from deviations in longitudinal data and traits related to animal resilience, health and welfare, such as tail and ear biting wounds, lameness and mortality.
RESULTS: In our experiment, 1919 finishing pigs with known pedigree (133 Piétrain sires and 266 crossbred dams) were weighed every 2 weeks and scored for physical abnormalities, such as lameness and ear and tail biting wounds (17,066 records). Resilience was assessed via deviations in body weight, deviations in weighing order and deviations in observed activity during weighing. The association between these resilience traits and physical abnormality traits was investigated and genetic parameters were estimated. Deviations in body weight had moderate heritability estimates (h2 = 25.2 to 36.3%), whereas deviations in weighing order (h2 = 4.2%) and deviations in activity during weighing (h2 = 12.0%) had low heritability estimates. Moreover, deviations in body weight were positively associated and genetically correlated with tail biting wounds (rg = 0.22 to 0.30), lameness (rg = 0.15 to 0.31) and mortality (rg = 0.19 to 0.33). These results indicate that events of tail biting, lameness and mortality are associated with deviations in pigs' body weight evolution. This relationship was not found for deviations in weighing order and activity during weighing. Furthermore, individual body weight deviations were positively correlated with uniformity at the pen level, providing evidence that breeding for these resilience traits might increase both pigs' resilience and within-family uniformity.
CONCLUSIONS: In summary, our findings show that breeding for resilience traits based on deviations in longitudinal weight data can decrease pigs' tail biting wounds, lameness and mortality while improving uniformity at the pen level. These findings are valuable for pig breeders, as they offer evidence that these resilience traits are an indication of animals' general health, welfare and resilience. Moreover, these results will stimulate the quantification of resilience via longitudinal body weights in other species.
OBJECTIVE: Our objective was to determine whether maternal blood angiogenic factors in suspected-small-for-gestational-age (sSGA) fetuses can predict critical adverse perinatal outcomes (CAPO) and improve risk assessment.
METHODS: Women with singleton pregnancies diagnosed with sSGA, between 24 and 356/7 weeks' gestation, were included. Clinical and sonographic comprehensive evaluations were performed at enrolment. Plasma angiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), were obtained at diagnosis. In parallel, three attending maternal-fetal-medicine specialists predicted the risk (1-5 scale) of these pregnancies to develop CAPO, based on the clinical presentation. CAPOs were defined as prolonged neonatal intensive care unit hospitalization, fetal or neonatal death, and major neonatal morbidity. Statistical analysis included sensitivity, specificity, positive and negative predictive values, and receiver-operating characteristic (ROC) curve analyses.
RESULTS: Of the 79 cases included, 32 were complicated by CAPO (40.5%). In SGA fetuses with CAPO, the sFlt-1/PlGF ratio was higher (p < 0.001) and PlGF was lower (p < 0.001) as compared with uncomplicated pregnancies. The areas under the ROC curves for specialists were 0.913, 0.824, and 0.811 and for PlGF and sFlt-1/PlGF ratio 0.926 and 0.900, respectively. CAPO was more common in pregnancies with absent end-diastolic flow or reversed end-diastolic flow (AEDF or REDF) in the umbilical artery upon enrolment (91.6%). Yet, 65.6% of cases involving CAPO occurred in patients without AEDF or REDF, and 66.6% of these cases were not identified by one or more of the experts. The sFlt-1/PlGF ratio identified 92.9% of the experts' errors in this group and 100% of the errors in cases with AEDF or REDF.
CONCLUSION: Among sSGA pregnancies prior to 36 weeks' gestation, angiogenic factors testing can identify most cases later complicated with CAPO. Our data demonstrate for the first time that these markers can reduce clinician judgment errors. Incorporation of these measures into decision-making algorithms could potentially improve management, outcomes, and even health care costs.
KEY POINTS: · Angiogenic factors at diagnosis of sSGA can be used to predict CAPO.. · The sFlt-1/PlGF ratio can flag sSGA pregnancies at increased risk.. · The sFlt-1/PlGF ratio at admission of sSGA adds to clinical assessment..
Given their highly polarized morphology and functional singularity, neurons require precise spatial and temporal control of protein synthesis. Alterations in protein translation have been implicated in the development and progression of a wide range of neurological and neurodegenerative disorders, including Huntington's disease (HD). In this study we examined the architecture of polysomes in their native brain context in striatal tissue from the zQ175 knock-in mouse model of HD. We performed 3D electron tomography of high-pressure frozen and freeze-substituted striatal tissue from HD models and corresponding controls at different ages. Electron tomography results revealed progressive remodelling towards a more compacted polysomal architecture in the mouse model, an effect that coincided with the emergence and progression of HD related symptoms. The aberrant polysomal architecture is compatible with ribosome stalling phenomena. In fact, we also detected in the zQ175 model an increase in the striatal expression of the stalling relief factor EIF5A2 and an increase in the accumulation of eIF5A1, eIF5A2 and hypusinated eIF5A1, the active form of eIF5A1. Polysomal sedimentation gradients showed differences in the relative accumulation of 40S ribosomal subunits and in polysomal distribution in striatal samples of the zQ175 model. These findings indicate that changes in the architecture of the protein synthesis machinery may underlie translational alterations associated with HD, opening new avenues for understanding the progression of the disease.
Lifestyle factors, such as diet and sleep quality, are receiving increasing interest as accessible therapeutic approaches to migraine. The Mediterranean diet (MD) has shown clear benefits in cardiovascular and metabolic diseases, as well as in sleep patterns. Here, our objective was to identify the impact of adherence to the MD and other lifestyle factors on the clinical burden of migraine. For this purpose, we enrolled 170 migraine patients and 100 controls, assessing the clinical disability of headache using standardized clinical scales (HIT-6 and MIDAS) in the migraineur cohort and lifestyle patterns in both groups through the PREDIMED score for MD adherence, the IPAQ scale for physical activity, and BMI. Subjects were also screened for sleep-wake disturbances based on the Pittsburgh Sleep Quality Index (PSQI). We found that migraine patients had lower adherence to the MD compared to the controls and that the HIT-6 scale had a significant negative relationship with MD adherence in patients with high-frequency episodic and chronic migraine. Additionally, in the same migraine patients, the presence of sleep-wake disturbances was correlated with greater migraine disability as assessed by the MIDAS score. In conclusion, this study found that among different lifestyle factors, poor adherence to the MD and the presence of sleep-wake disturbances were closely associated with migraine disability and chronification.